THE IMPACT OF INTERFERON VERSUS BUSULFAN THERAPY ON THE RETICULIN STAIN-MEASURED FIBROSIS IN CML - A COMPARATIVE MORPHOMETRIC STUDY ON SEQUENTIAL TREPHINE BIOPSIES
J. Thiele et al., THE IMPACT OF INTERFERON VERSUS BUSULFAN THERAPY ON THE RETICULIN STAIN-MEASURED FIBROSIS IN CML - A COMPARATIVE MORPHOMETRIC STUDY ON SEQUENTIAL TREPHINE BIOPSIES, Annals of hematology, 70(3), 1995, pp. 121-128
To evaluate treatment-related changes of the reticulin stain-measured
fibrosis in Ph(1+)-CML, a clinicopathological study was performed on s
equential trephine biopsies of the bone marrow following either interf
eron (IFN) or busulfan (BU) monotherapy. Using the monoclonal antibody
CD61 for the identification of megakaryopoiesis and Gomori's silver i
mpregnation method, number of megakaryocytes and density of ar gyrophi
lic (reticulin and collagen) fibers were determined by morphometry. We
studied specimens from 26 patients with IFN-alpha 2b (including nine
patients with additional IFN gamma) therapy and from 23 patients who h
ad received BU. In both groups, repeated bone marrow biopsies (total 1
25) revealed a significant increase in the fiber content, as well as i
n the number of megakaryocytes during treatment. To assess the dynamic
s of myelofibrosis more precisely, computation of differences in the d
egree of fiber density between the first and last examination was carr
ied out. Regarding the considerable variations in the biopsy intervals
, a so-called myelofibrosis progression index (MPI) was calculated. Fo
llowing this rationale, we were able to demonstrate that, in compariso
n to the BU-group, speed of progression of bone marrow fibrosis was si
gnificantly increased in CML patients treated with IFN. Preliminary st
atistical analysis indicated a relationship between myelofibrosis on a
dmission, which was always associated with increased growth of megakar
yocytes, and the MPI with survival. Even when these parameters were re
garded, prognosis was significantly more favorable in the IFN-treated
patients. The failure of IFN and BU to inhibit the evolution of myelof
ibrosis may be related to several conversely acting pathomechanisms. A
mong others, the inability of both therapeutic agents to reduce the nu
mber of megakaryocytes more effectively should be taken into considera
tion.